Brookline analyst Kemp Dolliver initiated coverage of Perspective Therapeutics (CATX) with a Buy rating and $11 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
- Perspective Therapeutics initiated with an Outperform at Scotiabank
- Promising Outlook for Perspective Therapeutics: Buy Rating Backed by Positive Trial Data and Market Positioning
- Perspective continues to pursue dose escalation of 212PbVMT-alpha-NET
- Perspective Therapeutics provides business updates, strategic priorities
Questions or Comments about the article? Write to editor@tipranks.com